[Changes in the percentage of activated lymphocytes in bronchoalveolar lavage fluid in patients with clinical improvement of sarcoidosis].
Sarcoidosis is characterized by an accumulation of the activated lymphocytes in affected organs. The aim of the study was the analysis of lymphocytes activation markers in a bronchoalveolar lavage fluid (BALF) in sarcoidosis and the influence of the disease outcome on the changes of cells subpopulations.


METHODS
We performed the study on 12 patients with the regression of sarcoidosis after the mean period of the observation 8.1 +/- 3.8 months.


RESULTS
We observed a tendency toward a BALF cellularity normalization: lowering of the percentage of CD4+ lymphocytes (mean: 67.1% vs. 57.8%, p = 0.047), lowering of the CD4+/CD8+ ratio (mean: 6.3 +/- 5.4 vs. 3.7 +/- 5.2, p < or = 0.05), lowering of the percentage of HLA-DR+ lymphocytes (mean: 65% < or = 16.4 vs. 43.9% +/- 18.0, p = 0.05), lowering of the percentage of CD25+ lymphocytes (mean: 5.7% vs. 3.1%, p < or = 0.05) and CD4+CD25+ (mean: 4.0% vs. 2.4%, p = 0.011).


CONCLUSIONS
The clinical improvement of sarcoidosis is accompanied by the lowering of the percentage of activated lymphocytes in BALF.
Piesiak
Paweł
P
Z Katedry i Kliniki Pulmonologii i Nowotworów Płuc Akademii Medycznej we Wrocławiu. p.piesiak@wp.pl
Jankowska
Renata
R
Passowicz-Muszyńska
Ewa
E
D000328:Adult; D015415:Biomarkers / Q000032:analysis; D001992:Bronchoalveolar Lavage Fluid / Q000276:immunology*; D016516:CD4-CD8 Ratio / Q000706:statistics & numerical data; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000473:pathology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000473:pathology; D015536:Down-Regulation; D005260:Female; D005938:Glucocorticoids / Q000494:pharmacology; D006684:HLA-DR Antigens / Q000276:immunology*; D006801:Humans; D007958:Leukocyte Count / Q000706:statistics & numerical data; D008213:Lymphocyte Activation; D018655:Lymphocyte Count / Q000706:statistics & numerical data; D008214:Lymphocytes / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000494:pharmacology; D012074:Remission Induction; D017565:Sarcoidosis, Pulmonary / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D016896:Treatment Outcome
D015415:Biomarkers; D005938:Glucocorticoids; D006684:HLA-DR Antigens; D011241:Prednisone